Gibson Christopher's Form 4 filing
Recursion Pharmaceuticals, Inc. (RXRX) · filed Apr 5, 2024
- Accession no.
- 0001628280-24-015103
- Filed
- Apr 5, 2024
- Trade date
- Apr 3-4, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 7 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.16M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gibson ChristopherCIK 0001856369 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 3, 2024 | Class A Common Stock | GGiftDisposed | −25,000 | $0.00 | $0 | 1,018,524 | Direct | |
| Apr 3, 2024 | Class A Common Stock | SSaleDisposed | −40,000 | $8.84 | −$353,600 | 978,524 | Direct | |
| Apr 4, 2024 | Class A Common Stock | SSaleDisposed | −40,000 | $9.02 | −$360,800 | 938,524 | Direct | |
| Apr 3, 2024 | Class A Common Stock | CConversionAcquired | +25,000 | $0.00 | $0 | 25,000 | Indirect | |
| Apr 3, 2024 | Class A Common Stock | SSaleDisposed | −25,000 | $8.84 | −$221,000 | 0 | Indirect | |
| Apr 4, 2024 | Class A Common Stock | CConversionAcquired | +25,000 | $0.00 | $0 | 25,000 | Indirect | |
| Apr 4, 2024 | Class A Common Stock | SSaleDisposed | −25,000 | $9.02 | −$225,500 | 0 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 3, 2024 | Class A Common Stock | CConversionDisposed | −25,000 | $0.00 | $0 | 67,875 | Indirect | |
| Apr 4, 2024 | Class A Common Stock | CConversionDisposed | −25,000 | $0.00 | $0 | 486,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.